<DOC>
	<DOCNO>NCT00997360</DOCNO>
	<brief_summary>This open label dose escalation study find maximum tolerate dose ( MTD ) PKI-179 subject solid tumor . Part 1 study dose estimation phase open subject solid tumor . Part 2 dose confirmation phase open subject breast , non small cell lung , ovarian , endometrial , colorectal cancer glioblastoma . All subject receive daily oral dose PKI-179 . A continuous reassessment method ( CRM ) design use , take account dose limit toxicity ( DLT ) information dose level explore order determine next dose level .</brief_summary>
	<brief_title>Study PKI-179 Administered Orally Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Male female subject age 18 year old . 2 . Part 1/MTD Estimation Phase : Pathologic diagnosis solid tumor . Part 2/MTD Confirmation Phase : Pathologic diagnosis one follow tumor type : breast , nonsmall cell lung , ovarian , endometrial , colorectal cancer glioblastoma . 3 . Availability either formalinfixed paraffinembedded ( FFPE ) tumor tissue block unstained slide exploratory biomarker analysis . 4 . Incurable cancer , disease progression follow least 1 conventional , standard , investigational therapy standard treatment available opinion investigator . 5 . At least 1 evaluable lesion define Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . 6 . Eastern Cooperative Oncology Group ( ECOG ) 0 2 . 7 . Acceptable laboratory value , include fast serum glucose . 8 . All male female subject biologically capable child , must agree use medically acceptable method birth control duration study ( e.g. , condom spermicide ) 12 week last dose investigational product . All female subject biologically capable child must negative serum pregnancy test result first dose investigational product . Any pregnancy occur female partner male subject trial must report occurs time active treatment phase study 12 week last dose investigational product . Exclusion criterion : 1 . Major surgery , chemotherapy , radiotherapy , investigational therapy , cancer therapy within 2 week prior first dose investigational product . 2 . Lack recovery prior surgery , chemotherapy , radiotherapy , cancer therapy . 3 . Clinically unstable primary metastatic central nervous system ( CNS ) tumor . Subjects progression CNS tumor eligible long clinically stable least 4 week first dose PKI179 ( significant change anticonvulsant dos , mental status , clinical symptom relate CNS tumor ) . 4 . Subjects know diabetes . 5 . QTc interval &gt; 470 ms. 6 . Pregnant breastfeed woman . 7 . Evidence significant medical illness abnormal laboratory find opinion investigator would substantially increase risk associate subject 's participation study impact assessment safety and/or efficacy . Examples include , limited : uncontrolled seizure , serious ongoing active infection require treatment , significant uncontrolled cardiac disease , congestive heart failure , myocardial infarction within past 6 month , angina require treatment , clinically significant uncontrolled condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Maximum tolerate dose</keyword>
	<keyword>Solid tumor</keyword>
</DOC>